Fresenius Kabi

Aktivs

• Fresenius Kabi Oncology - Produces ingredients for cancer drugs.

Employee salaries

The average salary at Fresenius Kabi Baltics as of June 2017 is 9,800 euros per month^[1].

Business in Russia

In June 2018, it became known that Roszdravnadzor, in fact, banned propofol, the drug Fresenius Kabi, with the help of which anesthesia was carried out in Moscow clinics, which possibly caused several deaths of patients. But this is not quite a ban - quarantine and selection of a certain batch of the drug^[2].

"Roszdravnadzor has been given the task of conducting quality tests of samples of this drug product taken from the hospital on the basis of the Moscow laboratory of Roszdravnadzor," the department explained. - The drug has now been moved to quarantine storage. The representative office of Fresenius Kabi Russia LLC has been notified of the need to immediately decide on the further circulation of the drug in the Russian Federation. "

Read more here.

History

2024: Recall of infusion pumps

On April 17, 2024, the U.S. Food and Drug Administration (FDA) announced the recall of defective Ivenix Infusion System (IIS) infusion pumps manufactured by Fresenius Kabi. The use of these devices can lead to serious harm to the health or death of the patient. Read more here.

2018

Recall of 163 batches of sodium chloride due to latex content in vials

On 28 Nov 2018, it was reported that Fresenius Kabi (Fresenius Kabi) voluntarily recalled 163 batches of sodium chloride, 0.9% USP injection solution in 10 and 20 ml vials. The reason was that latex was found in the rubber stoppers, while the instructions for use indicated that the stoppers did not contain latex.

Individuals with severe latex allergies may develop an anaphylactic reaction that may lead to hospitalization or death. According to Fresenius Kabi, no adverse events have yet been reported due to withdrawal of the injection solution.

The company also said it was taking all necessary measures to return the recalled product. At the same time, a corresponding written notification was sent to distributors and customers.^[3]

Cancellation of the deal with Akorn

On April 23, 2018, it became known about the decision of the German pharmaceutical company Fresenius Kabi to cancel the planned acquisition of Akorn for $4.3 billion. Fresenius Kabi explained its refusal to deal by the failure of the American pharmaceutical company to comply with a number of conditions necessary to complete the acquisition. The acquisition agreement of April 2017 provides for the payment of a commission upon termination in the amount of $129 million. Read more here.

2017: Akorn's $4.3 billion purchase plan

In April 2017, Fresenius Kabi announced the purchase of the American pharmaceutical company Akorn for $4.3 billion. It is planned to close the deal by early 2018. Read more here.

Notes